NCT03361748 : KarMMa - Phase 2 - To Determine the Efficacy and Safety of bb2121 in refractory MM
- Active, not recruiting
- Dec 5, 2017
- 3 min read
Updated: Oct 3, 2022
KarMMa
bb2121
NCT03361748: Phase 2 - Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)
Relapsed & Refractory Myeloma
NCT03361748: Phase 2 - Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)
This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T cells. Prior to bb2121 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.
Sponsor
Bristol Myers Squibb
ClinicalTrials.gov Identifier: NCT03361748
Official Title: A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
First Posted : December 5, 2017
Click here for details on ClinicalTrials.gov
Anti-BCMA CAR T Cells BB2121
anti-BCMA-CAR-transduced T cells BB2121
BCMA-specific CAR-expressing T lymphocytes BB2121
ide-cel
Abecma
BB2121
bb2121
Bluebird Bio
Idecabtagene Vicleucel
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
N Engl J Med: Feb 25, 2021
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
N Engl J Med. 2019 May 2
Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
ASCO Abstract 2020 - 8503
1739 Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial
Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Clinical: Poster I
Hematology Disease Topics & Pathways:
Cytokine Release Syndrome, Biological, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Clinically Relevant, Diseases, Therapies, Lymphoid Malignancies
Saturday, December 11, 2021, 5:30 PM-7:30 PM
11/04/2021: PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across a wide range of hematologic diseases at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place in Atlanta, Georgia, and virtually, from December 11 to 14, 2021. Data from more than 80 company-sponsored studies will be featured, including 23 oral presentations, highlighting key research and development programs in lymphomas, leukemias, multiple myeloma and myeloid diseases, and showcasing our commitment to delivering transformative medicines across major hematologic diseases.
Further analyses from the pivotal KarMMa trial in R/R multiple myeloma evaluated baseline predictors of complete responses and outcomes for patients treated with subsequent anti-myeloma therapies, including alternative B-cell maturation antigen (BCMA)-directed therapies, after treatment with Abecma (idecabtagene vicleucel), the first-in-class BCMA-directed CAR T cell therapy
Click here for details.
Meeting Abstract | 2021 ASCO Annual Meeting I
Hematologic Malignancies—Plasma Cell Dyscrasia
Journal of Clinical Oncology > List of Issues > Volume 39, Issue 15_suppl >
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
OAB-004 - Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed and refractory multiple myeloma: realworld experience
OAB-012 Early and sustained negative minimal residual disease (MRDneg) after idecabtagene vicleucel (ide-cel) defines a subset of multiple myeloma (MM) patients in KarMMa achieving prolonged survival -Bruno Paiva
#IMS2022 - 19th International Myeloma Society Annual Meeting; August 25-27, 2022 - LA, California
- California: University of California San Francisco
- Georgia: Emory University Atlanta
- Massachusetts: Massachusetts General Hospital Boston
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston
- Minnesota: Mayo Clinic Rochester Minnesota
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
- New Jersey: Hackensack University Medical Center
- Tennessee: Sarah Cannon Research Institute Nashville
- Texas: UT Southwestern Medical Center Dallas
Locations
United States, California
United States, Georgia
United States, Massachusetts
United States, Minnesota
United States, New Jersey
United States, New York
United States, Tennessee
United States, Texas
Canada
Europe
Belgium
France
Germany
Italy
Spain
Asia
Japan
RELATED POSTS
NCT03601078: KarMMa-2 - Phase 2 -Efficacy and Safety of bb2121 in relapsed & High Risk Myeloma (RRMM)
A Phase 2, Multicohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)
NCT03651128: KarMMa-3 - Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM)
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
NCT04196491: KarMMa-4 - Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM)
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4)
NCT04855136: KarMMa-7 - Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations (RRMM)
An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects With Relapsed/Refractory Multiple Myeloma (KarMMa-7)